United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

28 Apr 2017
Change (% chg)

$1.95 (+3.46%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pops, Richard 

Mr. Richard F. Pops is Chairman of the Board, Chief Executive Officer of Alkermes Plc. Prior to assuming his current positions, Mr. Pops served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 until September 2011. Mr. Pops serves on the board of directors of Neurocrine Biosciences, Inc., Acceleron Pharma, Inc. and Epizyme Inc., all of which are publicly traded biotechnology companies. Mr. Pops also serves on the board of directors of BIO and Pharmaceutical Research and Manufacturers of America ("PhRMA"). He has previously served on the board of directors of two other publicly traded biopharmaceutical companies, Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Incorporated from 2001 to 2009. Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He was a member of the Harvard Medical School Board of Fellows through June 2012. Mr. Pops is also a member of the FasterCures' Value & Coverage Advisory Council, which is designed to provide guidance on fostering a coverage and reimbursement environment that incentivizes biomedical innovation and ensures that patients have meaningful access to life-saving therapies. Mr. Pops' qualifications for our Board include his leadership experience, business judgment and industry knowledge. As a senior executive of Alkermes for almost 25 years, he provides in-depth knowledge of our company derived from leading our day-to-day operations. His ongoing involvement as a board member of BIO, PhRMA and FasterCures brings to the organization extensive knowledge of the current state of the pharmaceutical industry and the policy issues impacting healthcare today. As a Co-Chair of BIO's Regulatory Environment Committee, and a member of PhRMA's FDA and Biomedical Research Committee.

Basic Compensation

Total Annual Compensation, USD 881,019
Restricted Stock Awards, USD 2,849,200
Long-Term Incentive Plans, USD --
All Other, USD 8,677,270
Fiscal Year Total, USD 12,407,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 581,250 7,386,400.00
Name Fiscal Year Total

Richard Pops


Shane Cooke


James Frates


Kathryn Biberstein


Elliot Ehrich


Michael Landine

As Of  30 Dec 2015